Pembrolizumab Plus Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
Key Clinical Summary:
- Design/Population: In the phase 3 KEYNOTE-B96 trial, 643 patients with platinum-resistant ovarian cancer were randomized to receive pembrolizumab plus paclitaxel with or without bevacizumab.
- Key Outcomes: Pembrolizumab maintained quality of life and symptom burden compared with placebo, with similar or improved patient-reported outcomes across multiple measures. Time to deterioration was numerically longer in the pembrolizumab arm.
- Clinical Relevance: These findings suggest that adding pembrolizumab provides survival benefit without compromising quality of life. This supports its use as a treatment option in platinum-resistant ovarian cancer.
Emese Zsiros, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses patient-reported outcomes from the phase 3 KEYNOTE-B96 trial which randomized patients with platinum-resistant ovarian cancer to receive either pembrolizumab or placebo plus paclitaxel with or without bevacizumab.
Results from this double-blind, placebo-controlled trial demonstrate pembrolizumab plus chemotherapy maintains quality of life and symptom control while providing survival benefit.
Dr Zsiros presented these results at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in San Juan, Puerto Rico.
Source:
Zsiros E, Yin R, Gilbert L, et al. Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab versus placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer. Presented at SGO Annual Meeting on Women’s Cancer. April 10 - 13, 2026; San Juan, Puerto Rico. LBA7.
